Bayer had 30 patents in artificial intelligence during Q4 2023. Bayer AG’s patents in Q4 2023 focus on improving MRI examinations, enhancing crop yield through data analysis, determining pollen viability through image processing, predicting seed performance based on genetic features, and identifying chemical compounds with desired properties using machine learning. GlobalData’s report on Bayer gives a 360-degreee view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Bayer grant share with artificial intelligence as a theme is 26% in Q4 2023. Grant share is based on the ratio of number of grants to total number of patents.
Recent Patents
Application: Forecast of mri images by means of a forecast model trained by supervised learning (Patent ID: US20230410312A1)
See Also:
The patent filed by Bayer AG focuses on expediting MRI examinations through the use of a method, system, computer program product, contrast agent, and kit. The method involves receiving pre- and post-contrast MRI images of an examination region, feeding them into a prediction model trained through supervised learning, generating predicted MRI images for a specific time span, and displaying, outputting, or storing these images. The system includes a receiving unit, control and calculation unit, and output unit to facilitate the prediction and display of MRI images. Additionally, a computer program product is designed to execute the method steps. The contrast agent mentioned is a hepatobiliary contrast agent, specifically the disodium salt of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid, which is used to enhance imaging quality during the MRI process.
The patent also covers the use of the contrast agent in MRI methods, where the agent is administered, MRI images are generated, fed into a prediction model, and predicted images for a specific time span are displayed, outputted, or stored. The contrast agent, preferably containing gadoxetic acid or its salt, such as the disodium salt of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid, is crucial for enhancing the contrast and quality of the MRI images. The method and system described in the patent aim to streamline the MRI examination process, particularly for imaging liver or liver portions in different phases, ultimately improving diagnostic capabilities and efficiency in healthcare settings.
To know more about GlobalData’s detailed insights on Bayer, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
